Cargando…
Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions
BACKGROUND: XARTEMIS™ XR (formerly MNK-795) is a combination oxycodone (OC) and acetaminophen (APAP) analgesic with both immediate-release and extended-release (ER) components (ER OC/APAP). The tablets are designed with gastric-retentive ER oral delivery technology that releases the ER component at...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145823/ https://www.ncbi.nlm.nih.gov/pubmed/25170252 http://dx.doi.org/10.2147/DDDT.S64261 |
_version_ | 1782332225909424128 |
---|---|
author | Devarakonda, Krishna Morton, Terri Margulis, Rachel Giuliani, Michael Barrett, Thomas |
author_facet | Devarakonda, Krishna Morton, Terri Margulis, Rachel Giuliani, Michael Barrett, Thomas |
author_sort | Devarakonda, Krishna |
collection | PubMed |
description | BACKGROUND: XARTEMIS™ XR (formerly MNK-795) is a combination oxycodone (OC) and acetaminophen (APAP) analgesic with both immediate-release and extended-release (ER) components (ER OC/APAP). The tablets are designed with gastric-retentive ER oral delivery technology that releases the ER component at a controlled rate in the upper gastrointestinal tract. Because consumption of food has demonstrated an impact on the pharmacokinetics (PK) of some marketed products using gastric-retentive ER oral delivery technology, a characterization of the effects of fed (high- and low-fat diets) versus fasted conditions on the PK of ER OC/APAP was performed. METHODS: This Phase I study used an open-label randomized single-dose three-period six-sequence crossover single-center design. Healthy adult participants (n=48) were randomized to receive two tablets of ER OC/APAP under three conditions: following a high-fat meal; following a low-fat meal; and fasted. Plasma concentration versus time data from predose throughout designated times up to 48 hours postdose was used to estimate the PK parameters of oxycodone and APAP. RESULTS: Thirty-one participants completed all three treatment periods. Both oxycodone and APAP were rapidly absorbed under fasted conditions. Total oxycodone and APAP exposures (area under the plasma drug concentration-time curve [AUC]) from ER OC/APAP were not significantly affected by food, and minimal changes to maximum observed plasma concentration for oxycodone and APAP were also noted. However, food marginally delayed the time to maximum observed plasma concentration of oxycodone and APAP. There was no indication that tolerability was affected by food. CONCLUSION: The findings from this study suggest that ER OC/APAP can be administered with or without food. |
format | Online Article Text |
id | pubmed-4145823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41458232014-08-28 Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions Devarakonda, Krishna Morton, Terri Margulis, Rachel Giuliani, Michael Barrett, Thomas Drug Des Devel Ther Original Research BACKGROUND: XARTEMIS™ XR (formerly MNK-795) is a combination oxycodone (OC) and acetaminophen (APAP) analgesic with both immediate-release and extended-release (ER) components (ER OC/APAP). The tablets are designed with gastric-retentive ER oral delivery technology that releases the ER component at a controlled rate in the upper gastrointestinal tract. Because consumption of food has demonstrated an impact on the pharmacokinetics (PK) of some marketed products using gastric-retentive ER oral delivery technology, a characterization of the effects of fed (high- and low-fat diets) versus fasted conditions on the PK of ER OC/APAP was performed. METHODS: This Phase I study used an open-label randomized single-dose three-period six-sequence crossover single-center design. Healthy adult participants (n=48) were randomized to receive two tablets of ER OC/APAP under three conditions: following a high-fat meal; following a low-fat meal; and fasted. Plasma concentration versus time data from predose throughout designated times up to 48 hours postdose was used to estimate the PK parameters of oxycodone and APAP. RESULTS: Thirty-one participants completed all three treatment periods. Both oxycodone and APAP were rapidly absorbed under fasted conditions. Total oxycodone and APAP exposures (area under the plasma drug concentration-time curve [AUC]) from ER OC/APAP were not significantly affected by food, and minimal changes to maximum observed plasma concentration for oxycodone and APAP were also noted. However, food marginally delayed the time to maximum observed plasma concentration of oxycodone and APAP. There was no indication that tolerability was affected by food. CONCLUSION: The findings from this study suggest that ER OC/APAP can be administered with or without food. Dove Medical Press 2014-08-19 /pmc/articles/PMC4145823/ /pubmed/25170252 http://dx.doi.org/10.2147/DDDT.S64261 Text en © 2014 Devarakonda et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Devarakonda, Krishna Morton, Terri Margulis, Rachel Giuliani, Michael Barrett, Thomas Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions |
title | Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions |
title_full | Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions |
title_fullStr | Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions |
title_full_unstemmed | Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions |
title_short | Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions |
title_sort | pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of mnk-795, a dual-layer biphasic ir/er combination formulation, under fed and fasted conditions |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145823/ https://www.ncbi.nlm.nih.gov/pubmed/25170252 http://dx.doi.org/10.2147/DDDT.S64261 |
work_keys_str_mv | AT devarakondakrishna pharmacokineticsandbioavailabilityofoxycodoneandacetaminophenfollowingsingledoseadministrationofmnk795aduallayerbiphasicirercombinationformulationunderfedandfastedconditions AT mortonterri pharmacokineticsandbioavailabilityofoxycodoneandacetaminophenfollowingsingledoseadministrationofmnk795aduallayerbiphasicirercombinationformulationunderfedandfastedconditions AT margulisrachel pharmacokineticsandbioavailabilityofoxycodoneandacetaminophenfollowingsingledoseadministrationofmnk795aduallayerbiphasicirercombinationformulationunderfedandfastedconditions AT giulianimichael pharmacokineticsandbioavailabilityofoxycodoneandacetaminophenfollowingsingledoseadministrationofmnk795aduallayerbiphasicirercombinationformulationunderfedandfastedconditions AT barrettthomas pharmacokineticsandbioavailabilityofoxycodoneandacetaminophenfollowingsingledoseadministrationofmnk795aduallayerbiphasicirercombinationformulationunderfedandfastedconditions |